Evidence map›Paper›PMID 34835379›Full record

ArticleMicroorganisms2021

Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE Adjuvant.

Laura Fernández, Jose Carlos Solana, Carmen Sánchez, Mª Ángeles Jiménez, Jose M Requena, Rhea Coler, Steven G Reed, Jesus G Valenzuela, Shaden Kamhawi, Fabiano Oliveira and 10 more

Open access · goldAbstract read
In one paragraph

Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024
    Review
  5. Advances inMicroorganisms · 2023
    Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 4 countries.

Laura FernándezWHO Collaborating Centre for Leishmaniasis, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Madrid, Spain.
Jose Carlos SolanaWHO Collaborating Centre for Leishmaniasis, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Madrid, Spain.ORCID 0000-0002-0485-6127
Carmen SánchezWHO Collaborating Centre for Leishmaniasis, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Madrid, Spain.
Mª Ángeles JiménezFacultad de Veterinaria, Departamento de Medicina y Cirugía Animal, Universidad Complutense de Madrid, 28040 Madrid, Spain.
Jose M RequenaCentro de Biología Molecular Severo Ochoa (CSIC-UAM), Universidad Autónoma de Madrid, 28049 Madrid, Spain.ORCID 0000-0001-7550-0198
Rhea ColerCenter for Global Infectious Disease Research (CGIDR), Seattle Children's Research Institute, Seattle, WA 98109, USA.
Steven G ReedHDT Bio Corp, Seattle, WA 98102, USA.
Jesus G ValenzuelaVector Molecular Biology Section, Laboratory of Malaria and Vector Research, NIAID, NIH, Rockville, MD 20852, USA.
Shaden KamhawiVector Molecular Biology Section, Laboratory of Malaria and Vector Research, NIAID, NIH, Rockville, MD 20852, USA.
Fabiano OliveiraVector Molecular Biology Section, Laboratory of Malaria and Vector Research, NIAID, NIH, Rockville, MD 20852, USA.
Epifanio FicheraEtna Biotech S.R.L, 95121 Catania, Italy.
Reinhard GlueckEtna Biotech S.R.L, 95121 Catania, Italy.
Maria Elena BottazziDepartment of Pediatrics, Texas Children's Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USA.ORCID 0000-0002-8429-0476
Gaurav GuptaEtna Biotech S.R.L, 95121 Catania, Italy.
Pedro CecilioParasite Disease Group, Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0001-5945-5040
Begoña Pérez-CabezasParasite Disease Group, Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, 4200-135 Porto, Portugal.
Anabela Cordeiro-da-SilvaParasite Disease Group, Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0003-2392-6087
Luigi GradoniUnit of Vector-Borne Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0003-0949-6818
Eugenia CarrilloWHO Collaborating Centre for Leishmaniasis, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Madrid, Spain.ORCID 0000-0002-7869-7915
Javier MorenoWHO Collaborating Centre for Leishmaniasis, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Madrid, Spain.ORCID 0000-0003-0087-4659
Instituto de Salud Carlos III · ESEtna Biotech (Italy) · ITUniversidade do Porto · PTVector Oncology (United States) · USBaylor College of Medicine · USCentro de Biología Molecular Severo Ochoa · ESInfectious Disease Research Institute · USIstituto Superiore di Sanità · ITUniversidad Complutense de Madrid · ES

Funding

European Community's Seventh Framework Programme 603181Red de Investigación Cooperativa de Enfermedades Tropicales, Subprograma RETICS del Plan Estatal de I+D+I 2013-2016, co-funded by ERDF "Una manera de hacer Europa RD16/0027/0008Red de Investigación Cooperativa de Enfermedades Tropicales, Subprograma RETICS del Plan Estatal de I+D+I 2013-2016, co-funded by ERDF "Una manera de hacer Europa RD16CIII/0003/0002
6 · The paper itself

Abstract

Visceral leishmaniasis (VL) is the most severe clinical form of leishmaniasis, fatal if untreated. Vaccination is the most cost-effective approach to disease control; however, to date, no vaccines against human VL have been made available. This work examines the efficacy of a novel vaccine consisting of the

Indexed as

GLA-SEhamsterKMP11LEISH-F3leishmaniasisLJL143vaccinevirosomes

Identifiers

PMID34835379
PMCPMC8618729
OpenAlexW3210340587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.